SAVIOUR AYIM: Open Payments
NPI 1962078113 · WEST ORANGE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$667 in 23 payments from 6 companies in 2025. Trend: 2023 $45 · 2024 $1,363 · 2025 $667
Food & beverage: $667
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $356 |
| Teva Pharmaceuticals USA, Inc. | 4 | $161 |
| E.R. Squibb & Sons, L.L.C. | 5 | $86 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Luye Pharma (USA) Ltd. | 1 | $17 |
| Neurocrine BioSciences, Inc. | 1 | $16 |
Products named: LYBALVI, UZEDY, ARISTADA, COBENFY, ABILIFY MAINTENA, ERZOFRI EXTENDED-RELEASE, INGREZZA.
Industry payments across NJ — which companies pay providers there.
